Nycomed sees return of price squeeze in U.S.

Article

Price pressure has returned to the U.S. contrast agent market after a brief period of relative stability, Norwegian contrast developer Nycomed reported late last month. Nycomed attributed the resurgence to heavier competition in the contrast market, as

Price pressure has returned to the U.S. contrast agent market after a brief period of relative stability, Norwegian contrast developer Nycomed reported late last month. Nycomed attributed the resurgence to heavier competition in the contrast market, as well as increased managed-care buying power and the consolidation of group purchasing organizations.

Nycomed's announcement echoes comments made by Mallinckrodt executives last month on the status of the U.S. market for contrast media (SCAN 10/1/97). Mallinckrodt said that heightened price pressure in the U.S. market would cause the company to report lower than expected earnings for the first quarter of fiscal 1998.

Nycomed's news on contrast pricing came as part of an update on the status of the company's proposed merger with Amersham International of the U.K. The merger proposal will be voted on by shareholders of both companies at meetings to be held Oct. 14 and 16. The expected closing date of the deal is Oct. 21.

In other Nycomed news, the company announced in September that it has been awarded a three-year contract to supply x-ray and MRI contrast products to University HealthSystem Consortium Services. Nycomed has also submitted a bid in connection with the renegotiation of a supply agreement it holds with another GPO that is set to expire at the end of this year.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.